Cannabis U.S. Companies

[Robertscott]

$WDRFF $WNDR Latest Updates on PST - http://www.pennystocktweets.com/stocks/profile/WDRFF

[Golden Cross]

$PAOG New MJ Entity Acquisition

https://www.nasdaq.com/press-release/pao-group-proudly-announces-new-mj-entity-acquisition-20190110-00763

[Robertscott]

$RSCZF Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN) is a medical marijuana pharmaceutical company headquartered in Toronto, ON with its research and development team at the University of Oxford.

The company is led by world class scientist, CEO and CSO, Professor Jagdeep Nanchahal, of the University of Oxford. Signals that the body's own stem cells that induce repair of tissues can be made to function more efficiently, have been identified by Prof. Nanchahal's team.

[Bansky]

$EBYH stock is bouncing. Expect several news releases on major cannabis APP launch. 200 thousand shares in float.

http://strainsforpains.com/

https://www.facebook.com/Strainsforpains-Inc-981797461869916/

https://www.otcmarkets.com/stock/EBYH/security

[JohnCM]

$30.00 !!!

Etfmg Alternative Ha (MJ)
29.35 +0.36 (1.24%)
Volume: 734,956 @ 1:18:50 PM EST ET
Bid Ask Day's Range
- - 28.6 - 30.0

[Robertscott]

$WDRFF $WNDR News after hours from Tuesday https://finance.yahoo.com/news/correction-wonderfilm-sets-six-films-070100770.html

[JohnCM]

That last dip was brutal for everyone.

[greenwillow]

2019 will be the year for TGIFF, imo

1933 industry's

[Jaymeinnyc]

Exclnt thanks for this

[JohnCM]

Companies added to the United States Marijuana Index include:

• 1933 Industries Inc. – A vertically integrated cannabis company with operations in the U.S. and Canada.

• Acreage Holdings. Inc. – A vertically integrated cannabis company with cultivation, processing and dispensing operations covering 12 states.

• Cresco Labs, Inc. – A grower, processor and retailer of premium cannabis operating in seven states, the company focuses on entering highly regulated markets with outsized demand potential and high barriers to entry.

• Curaleaf Holdings, Inc. – A leading vertically integrated cannabis operator focused on highly populated, limited license states, with operations in 12 states.

• Harvest Health & Recreation Inc. - Holds medical cannabis licenses in nine states and participate in a variety of ways for each facility.

• MJardin Group, Inc. – A global cannabis management platform with extensive experience in cultivation, processing, distribution and retail.

• Planet 13 Holdings Inc. – A vertically integrated cannabis company based in Nevada, with cultivation, production and dispensary operations in Las Vegas.

• TILT Holdings Inc. – A vertically-integrated technology and infrastructure company that provides the most comprehensive range of products and services in the cannabis industry.

• Trulieve Cannabis Corp. – The first and leading medical cannabis company in the state of Florida.

• Green Growth Brands. – Holding company with multiple subsidiaries including dispensary, cultivation and consumer-facing products.

[Ryguy008]

$PLPL no brainer here. Huge squeeze, not nearly close to done yet. Yesterday’s million slaps at HOD taking this another day. Big update coming

[jedijazz]

EPAZ Hemp is nearly identical to marijuana. American Farmers will be able to grow hemp legally in the US. They will need a software to track the plant and provide data to the US government. According to Business Insider, Industrial hemp is expected to be a 1 billion dollar industry.

https://seekingalpha.com/pr/17357385-epazz-plant-tracker-software-benefit-us-farm-bill-legalization-industrial-hemp

[budfoxfun]

$IDVV CBD topped $350 Million in consumer sales in 2017 https://finance.yahoo.com/news/idvv-retains-counsel-obtain-cultivation-100000678.html

[weedtrader420]

((reac))next biggest boom will be real estate land to grow hemp. buying reac

[budfoxfun]

$IDVV the consumer sales of CBD products last year topped $350 million in the United states, more than triple the amount sold in 2014, and various estimates predict the market could reach $2 billion within the next two to four years.

[Robertscott]

$MCOA About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA's jurisdiction.

[JohnCM]

Liberty Health Sciences to Launch Zentient Labs CBD Portfolio of Products

December 21, 2018

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com, a provider of high quality cannabis, today announced the launch of Zentient Labs, a line of premium hemp-based CBD products made from a proprietary formula of ultra-high quality CBD, nutraceuticals and vitamins that promote energy and focus for wellness seekers.

The CBD market is experiencing dramatic growth and is predicted to grow to $2.1 billion in consumer sales by 2020, with $450 million of those sales coming from hemp-based sources. Demand for CBD has also increased rapidly due in large part to the wide variety of ways it can be used in products, ranging from food and cosmetics to beverages and a myriad of health supplements.

"Liberty Health Sciences is quickly becoming a leading cultivator and distributor of premium cannabis products through low-cost production techniques and high-end dispensary design and intends to apply the same techniques to the cultivation and distribution of hemp-derived products," said George Scorsis, CEO of Liberty Health Sciences. "We currently operate two facilities in Florida with a total cultivation capacity of over 41,000 square feet.

"The Company has increased its cultivation capacity to more than 120,000 square feet and will grow to approximately 225,000 square feet by early 2019. Our processing facility utilizes state-of-the-art equipment and techniques for extraction and purification and our experience with medical marijuana is directly applicable to industrial hemp," said Scorsis.

Zentient Labs will include a line of products across numerous categories including propriety brands and partner brands. These categories will include an athletic line, a wellness line, beauty and premium pet products.

Liberty carefully selected the brand name Zentient Labs to deliver on a promise to provide high-quality CBD products to customers who seek out creative pursuits, the deepest of relaxation and the most aggressive sports activities. The Company did extensive consumer research to define what this brand will represent.

"Zentient Labs' line of wellness products was designed to support your desired activity, so you can be in the 'Zentient Zen state', as we call it," said Stephanie Kubacki, Vice President of Marketing, Liberty Health Sciences. "When 'in the zone', you become one with the activity, lost in the rhythm of the tasks at hand. It's characterized by complete connectedness and presence, being solely focused on that exact moment in time. This is what our exciting line of products looks to support. Let's face it, with the pace of life these days, many of us strive to be more conscious and in the now."

Liberty used the services of Theory SF www.theorysf.com, a multi-disciplinary marketing agency located in the heart of San Francisco to create the Zentient Labs brand image.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty's measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.

[JohnCM]

TerrAscend Enters U.S. Hemp Market with $13 Million Acquisition

December 24, 2018 at 9:51 am
Published by NCV Newswire

TORONTO, Dec. 24, 2018 /PRNewswire/ – TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend”) today announced the signing of a definitive agreement (the “Agreement”) to acquire substantially all of the assets of Grander Distribution, LLC (“Grander” or the “Seller”). Grander is an industry leader in the production and distribution of innovative hemp-derived wellness products.

Their whole-plant hemp extract products are made in the USA and are available for sale in ~10,000 retail locations worldwide. Grander expects 2018 sales to exceed US$10,000,000 with the most recent one month run rate of over US$14,000,000 on an annualized basis. The US$13,000,000 purchase price is an equal combination of cash and stock with the potential for additional consideration of up to US$10,000,000 based on revenue targets of US$35,000,000 in 2019 and US$50,000,000 in 2020. The transaction is expected to close by January 15, 2019, upon completion of standard closing requirements.

"We are thrilled to welcome the Grander team and look forward to leveraging their expansive distribution and branding expertise as we complete the first acquisition of our US strategy. In addition to their seasoned sales force, Grander has a proven track-record of driving the development, manufacturing and processing of innovative hemp-derived cannabinoid products."

Matthew Johnson, President TerrAscend Corp., and TerrAscend USA, Inc.
“With the passing of the 2018 US Farm Bill, and the closing of this transaction, TerrAscend will be well positioned to take advantage of the substantial hemp-derived product opportunity.”

"We couldn’t be more excited to join forces with TerrAscend. The collaboration of talent and expertise across the combined organization will give TerrAscend a significant competitive advantage in developing, marketing, and supplying the most cutting-edge products in the hemp-derived cannabinoid market."

Scott Frohman, CEO of Grander

About TerrAscend Corp.

TerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. TerrAscend provides support to patients and consumers through its wholly-owned subsidiaries, TerrAscend Canada Inc., a licensed producer of cannabis pursuant to the Cannabis Regulations under the Cannabis Act (Canada) that provides medical cannabis to patients through its online medical marketplace Solace Health, and Solace Health Network Inc., a clinical support program and education platform led by healthcare professionals. TerrAscend participates in the legal adult-use market in Canada through direct and indirect supply agreements in several provinces and intends to expand into the US market in states where cannabinoids have been legalized for therapeutic or adult-use. TerrAscend also launched Ascendant Labs, a company committed to the continuous improvement of cannabinoid expressing plants, which is a strategic joint venture with leading researchers Cistron Corp.

[JohnCM]

Cresco and Acreage making nice moves ...

[JohnCM]

Futures point to US stock gains as the Dow attempts to rebound from its worst week in a decade

PUBLISHED SUN, DEC 23 2018 6:05 PM
John Melloy

U.S. stock futures rose after earlier falling slightly during trade on Sunday evening stateside. as the market attempts to rebound from a brutal week that pushed stocks to the brink of a bear market.
Treasury Secretary Steven Mnuchin held calls on Sunday with the heads of the six largest U.S. banks in order to reassure nervous investors.

U.S. stock futures recovered from their earlier losses to see gains on Sunday evening as the market attempts to rebound from a brutal week that pushed the S&P 500 to the brink of a bear market.

Dow Jones Industrial Average futures rose 106 points, implying an opening gain for the Dow of 76.63 points, as of 9:30 p.m ET Sunday. They had earlier fallen shortly after the open of trading. S&P 500 futures and Nasdaq 100 futures also pointed to gains at the open.

The Dow lost 1,655 points, or 6.8 percent, last week for its worst week since October 2008 during the financial crisis. The S&P 500 lost 7 percent for the week and is now down 17.8 percent from its record reached earlier in the year, putting it on the brink of a bear market. The Nasdaq Composite Index is now 22 percent below its record reached in August, a bear market.

Last Wednesday, the Federal Reserve raised its benchmark interest rate for a fourth time this year and Chairman Jerome Powell signaled the central bank would continue to unwind its balance sheet at the current pace. The two monetary tightening actions are driving the stock market declines, traders say.

Treasury Secretary Steven Mnuchin held calls on Sunday with the heads of the six largest U.S. banks in order to reassure nervous investors that the financial markets and economy were functioning properly.

“The banks all confirmed ample liquidity is available for lending to consumer and business markets,” the statement from the Treasury said.

“We continue to see strong economic growth in the U.S. economy with robust activity from consumers and business,” said Mnuchin added in the statement.

Late Friday, there was a report that President Donald Trump was discussing the possibility of firing Powell, a move that could undermine confidence in the U.S. financial system. Other media outlets later confirmed those reports, but Mnuchin sought to from those reports this weekend.

Mnuchin tweeted that he spoke with the president and Trump said he never suggest firing Powell and doesn’t believe he has the right to do so.

Steven Mnuchin

@stevenmnuchin1
(1/2) I have spoken with the President @realDonaldTrump and he said “I totally disagree with Fed policy. I think the increasing of interest rates and the shrinking of the Fed portfolio is an absolute terrible thing to do at this time,...

Steven Mnuchin

@stevenmnuchin1
(2/2) especially in light of my major trade negotiations which are ongoing, but I never suggested firing Chairman Jay Powell, nor do I believe I have the right to do so.”

Also weighing on investor confidence is a government shutdown that on through at least Thursday.

Both the Dow and the S&P 500 are now in the red for 2018 by at least 9 percent. Some traders have suggested that the market has gotten to the point where a short-term bounce could occur, if only for technical reasons. Seasonally, this is usually a positive, or at least benign, time for the markets.

The NYSE closes early on Monday at 1 p.m. ET. The exchange is closed on Tuesday for Christmas day. Wednesday through Friday are normal trading days.

[DGStocks]

[JohnCM]

Crop Infrastructure (CRXPF)
0.23 -0.0239 (-9.41%)
Volume: 450,423 @ 5:20:01 PM EST ET
Bid Ask Day's Range
0.222 0.257 0.225 - 0.2701

[Robertscott]

$ETST Company Takes Advantage of Farm Bill Opportunities, Signs New Chief Sales Officer to Distribute CBD Products Through Nationwide Chain Retailers

[JohnCM]

BIG

Tilray Signs Deal With Big Pharma Company Sandoz ]
Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ: TLRY) entered into an agreement with Sandoz AG, which is a part of the Novartis group, to increase the availability of high-quality medical cannabis products across the world..

.

[BottomBounce]

Massive $867 Billion Farm Bill Pushes Hemp Legalization Near the Finish Line, Hemp, Inc. $HEMP Reports https://globenewswire.com/news-release/2018/12/12/1666054/0/en/Massive-867-Billion-Farm-Bill-Pushes-Hemp-Legalization-Near-the-Finish-Line-Hemp-Inc-Reports.html …

[JohnCM]

Might be the bottom for Acreage.

In case anyone was interested in investing.

11.99

[JohnCM]

27.31 RSI(14)

[JohnCM]

Cannabis Attracts Big Tobacco, Alcohol, and Pharma. Which Big Industries Will Join Next?

Kris Krane - Forbes
Dec 19, 2018

The era of big business entering cannabis officially began in 2018

Altria Group Inc., the world’s largest tobacco company and owner of Philip Morris and Marlboro cigarettes, recently made a $1.8 billion investment in Canadian cannabis producer Cronos for 45% of the company.

The big news in cannabis over the past couple of weeks has been the announcement that Altria, the world’s largest tobacco company and owner of Philip Morris and Marlboro cigarettes, made a $1.8 billion investment in Canadian cannabis producer Cronos for 45% of the company. The deal comes with warrants for Altria to provide an additional $1.05 billion for a 55% stake in Cronos.

Then, just yesterday, Tilray announced an expanded strategic partnership with Novartis, the pharmaceutical giant, to work on medical cannabis products in legal markets.

These developments of course come on the heels of the other major news from earlier this year, when alcohol giant Constellation Brands bought a 38% stake in the largest Canadian cannabis company, Canopy Growth, for $4 billion. This deal, which was preceded by a smaller investment in October 2017 by Constellation into Canopy, similarly came with warrants that will allow Constellation, the maker of Corona beer and Svedka vodka, to buy a majority interest in Canopy.

The ramifications of this are clear and stark. By the end of 2019, there is a realistic chance that two of the largest cannabis companies in the world will be owned by two of the largest alcohol and tobacco companies in the world. The era of big business entering cannabis officially began in 2018 .

The year also saw other major companies dip a toe in the cannabis market. Molson (a subsidiary of Coors) announced a partnership with Hydropothecary to create a line of non-alcoholic cannabis infused beer.

Coca-Cola is rumored to be exploring a partnership with Aurora that would allow them to make CBD-infused beverages, something that may be closer to a reality with CBD-hemp production and extraction becoming legal as part of the recently passed Farm Bill.

We also saw a major increase in merger-and-acquisition activity among American cannabis operators in the past year, which may also portend the entry of major industry players in cannabis as multi-state operators position themselves as attractive acquisition targets for big moneyed players from outside the industry. Just this year we saw the announced mergers of industry heavyweights MedMen and Pharmacann, iAnthus and MPX, and my own company 4Front with Cannex. This happened during a flurry of smaller and mom-and-pop operators being acquired by the larger multi-state companies.

Looking towards the future, this consolidation makes sense. On an operational level, companies are able to build economies of scale with more licenses in more states, and are largely rewarded by investors and the public markets for doing so. But these companies are also well positioned to be acquired by much larger companies from other sectors once federal cannabis prohibition ends and these companies feel comfortable entering the multi-billion dollar American cannabis market. When companies with billions of dollars to spend on acquisitions decide they want in on the U.S. cannabis market, some of them may not want to do the grinding hard work of rolling up dozens of smaller operators across multiple states. Instead, many will likely look for larger companies with developed brands, capabilities and existing distribution networks.

So who are these companies waiting in the wings to jump into the American cannabis market? We’ve already seen alcohol and tobacco get involved in Canada, and there’s no doubt they’re keeping similar tabs on the United States. Altria may have been the first tobacco company to buy a stake in a cannabis license, but you can be certain its competitors will ensure that they are not the last. Similarly, Constellation and Molson will certainly be joined by other alcohol manufacturers in partnering with and acquiring American cannabis businesses once there is an adequate change in federal law. Some will be large deals like Constellation’s with Canopy, while others may see craft brewers and micro-distillers teaming up with craft cannabis producers to create a truly high-end user experience for fans of both products.

But alcohol and tobacco are hardly the only industries set to expand into the growing cannabis economy. Other industries like pharma, agriculture, and non-alcoholic beverages can all benefit from an end to cannabis prohibition.

Big Pharma

The pharma industry is the most profitable industry in the United States today, and its members no doubt have interest in the healing properties contained in cannabis, as evidence by Novartis’ recent partnership with Tilray.

Cannabis has been part of the U.S. pharmacopeia dating back to the founding of the country, and only became shunned by the medical community after cannabis became outlawed federally in 1937 over the objections of the American Medical Association. But since 1996, Americans have been able to treat conditions from glaucoma to multiple sclerosis to insomnia with cannabis.

While pharma companies can’t patent whole smoked cannabis as pharmaceutical drugs, they can and will create drugs based on the cannabinoids and terpenes found in this healing plant. GW Pharmaceuticals, a British-based company focused on the development of cannabinoid based medications had a breakthrough this year when the FDA approved Epidiolex, a CBD-based drug derived from the cannabis plant, as a prescription medication in the United States. The company’s first product, Sativex, has already been available in pharmacies across Europe and Canada for nearly a decade.

No doubt major pharma companies like Pfizer and Bayer are watching the cannabis industry closely and exploring the possibility of following GW’s lead in developing a new generation of life-altering, cannabinoid-based medications.

Agriculture

Of course, cannabis is an agricultural crop, which means it must have the attention of large-scale commercial agriculture companies. When federal prohibition ends, and once interstate commerce and cross-border imports have fully opened up, most cannabis cultivation will likely move to massive scale fields with large drops in wholesale pricing. Most experts agree that cannabis production will commoditize, and as this happens agriculture giants will be best positioned to bring their efficiencies at scale to this industry, as well as their technology for optimizing genetics, propagation, and other techniques not currently available in the cannabis industry. We’ve already seen Scotts Miracle-Gro embrace the cannabis industry. It seems to be only a matter of time before companies like Monsanto enter the fray.

Food & Beverage Companies

We’ve seen a recent trend towards cannabis-infused drinks and compound formulations for infusion into other products. Coca Cola looking at CBD-infused beverages is likely only the beginning. It would seem a natural fit for companies like Coca Cola or Pepsi to eventually partner with companies like Dixie Elixers or Keef Cola to create entire skews of cannabis-infused beverages. Similarly, chocolate makers like Hershey and Nestle must be intrigued by the success of Kiva Chocolates, Incredibles, and other successful cannabis confectioners.

Technology & Ancillary Service Providers

On the technology side, companies like MJ Freeway, Biotrack and Greenbits would make great acquisition targets for large-scale, point-of-sale companies from other industries. Delivery companies like Eaze and Meadow would make natural partners or acquisition targets for Uber Eats or DoorDash. Companies that aggregate cannabis industry data like BDS Analytics and New Frontier would make great partners for major business data aggregators like Bloomberg and Neilson.

While 2018 marked the first stage of some pioneering companies in traditional industries entering the cannabis market, the coming years will involve more partnerships, mergers, and acquisitions between cannabis operators and major companies from other industries. Of course, federal cannabis prohibition remains a major impediment to traditional companies’ full-scale embrace of cannabis in the United States, but when prohibition does end, there is going to be a large influx of traditional companies getting into cannabis. This article only scratches the surface; the market will surely come with plenty of surprises.

[JohnCM]

Market Summary > ACREAGE HOLDINGS ORD
OTCMKTS: ACRZF
24.44 USD +1.44 (6.26%)
Nov 26, 4:00 PM EST · Disclaimer

[JohnCM]

Epazz is having a hard time getting untracked.

[jedijazz]

$EPAZ Epazz Plant Tracker Software to Benefit from US Farm Bill Legalization of Industrial Hemp https://finance.yahoo.com/news/epazz-plant-tracker-software-benefit-133000582.html

[budfoxfun]

$IDVV CBD products have become increasingly popular in recent years, as it is marketed more and more as the new "it" drug for the health and wellness set - one that has been touted as a pain reliever and a treatment for anxiety, among other potential applications. Last year, consumer sales of CBD products topped $350 million in the United states, more than triple the amount sold in 2014, and various estimates predict the market could reach $2 billion within the next two to four years.

The term "CBD" is a nickname for cannabidiol, which is one of several cannabinoids, or chemical compounds, that are found in cannabis and hemp plants. The most popular cannabinoid is tetrahydrocannabinol, or THC, which is the main psychoactive component in marijuana, the part that gets you high. Because CBD is not psychoactive, it does not create the same buzzy effects typically associated with marijuana when ingested.

[drew5]

MRMD took a beating today. Its a BUY IMO.

[seventhcircle]

$etst looking strong on news this morning ready for another 1.00+ run with farm bill passing imo

[seventhcircle]

$igpk a new hemp stock worth looking into. 3 years of filings were uploaded to the OTC markets. Pink current coming and more updates per company tweet. $igpk

[jedijazz]

$IDVV The term "CBD" is a nickname for cannabidiol, which is one of several cannabinoids, or chemical compounds, that are found in cannabis and hemp plants. The most popular cannabinoid is tetrahydrocannabinol, or THC, which is the main psychoactive component in marijuana, the part that gets you high. Because CBD is not psychoactive, it does not create the same buzzy effects typically associated with marijuana when ingested.

[JohnCM]

Liberty Health Sciences Experiences a Significant Increase in Year-Over-Year Revenue and Provides Update on its Liberty 360 and Ohio Operations

TORONTO, Dec. 7, 2018 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that they experienced a significant increase in sales revenue in the quarter ended November 30, 2018 compared to the same period in the prior year. For the quarter ended November 30, 2018, revenue increased by 45% compared to the quarter ended August 31, 2018.

Liberty's recent quarterly revenue totaled $3.2 million and its fiscal year-to-date revenue totaled $6.5 million. This continued growth in revenue reflects the Company's improvement on returning patient count and the expanding dispensary base, as well as the strength of its partnerships with best-in-class brands such as PAX and Mary's Medicinals.

Liberty's patient count increased by 46% during the quarter ended November 30, 2018 to approximately 14,500 patients. Supporting this growth is Liberty's accelerated pace in opening dispensaries, adding three additional dispensaries over the last quarter for a total of seven dispensaries and six delivery hubs opened to date. Liberty expects to open another seven dispensaries by the end of February 2019 to a total of 14 dispensaries across Florida, including locations in Miami, Boca Raton and Gainesville, subject to the receipt of all necessary approvals from the Florida Department of Health. Under the state regulations, the Company is entitled to open up to 30 dispensaries. Accordingly, Liberty will continue to seek suitable locations in response to the state's growing patient count.

"We are happy with the progress we are making as we continue to move forward on both dispensary openings and operational capacity," said George Scorsis, CEO of Liberty Health Sciences. "Liberty remains committed to growth and operational excellence across Florida and to potential expansion opportunities in other states."

In support of the ongoing opening of its dispensary locations, Liberty expects to finish construction in phases on the planned 225,000 square feet Liberty 360 facility including the state-of-the-art processing and production space in 2019. Liberty is currently operating 20,000 square feet of cultivation space at the Liberty 360 property as well as 24,000 square feet at the original Alachua property to support the growing demand for product. The next phase, expected to be completed in early 2019, will add 80,000 square feet of cultivation space. Liberty is fully funded to complete these capital expenditures.

"Our cultivation team is doing an excellent job and we continue to get amazing yields from our operations," said Lewis Swarts, VP Operations of Liberty Health Sciences. "The automation we have introduced into our processing operations is paying dividends as we are able to keep up with the increase in demand from our growing patient base."

In addition to the expanded cultivation and processing space, the facility will also include a state-of-the-art research and development lab. With the completion of the processing plant, Liberty's extraction capacity will increase by nine times its current level.

The completion of Liberty 360 will allow Liberty to significantly increase its production capacity, expand its product line and provide scientific and technical support for Liberty's operations in other states. Liberty currently employs just under 200 people across its operations and dispensaries. With the anticipated completion of Liberty 360, the Company expects to employ a diverse workforce of up to 500 people including patient liaisons, scientists, engineers and cultivation specialists.

In Ohio, Liberty, together with their joint venture partners, the Schottenstein Group, expects to open their dispensary in Dayton, Ohio at the end of March 2019. Its processing facility will open subsequent to that in the spring of 2019, each depending on the receipt of the required regulatory approvals. The joint venture has secured a 10,000 square foot processing facility, which will be used for extraction, refining, formulation and packaging.

"Liberty is committed to bringing the same high-quality offerings to Ohio as we have in Florida," said Scorsis. "With the knowledge base gained over our last year of operation, we believe we have the team and tools to continue to succeed."

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty's measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.

[JohnCM]

TRULIEVE

Great interview with Kim Rivers. Podcast Don't miss it:https://themarijuanasolution.com/kim-rivers-ceo-of-trulieve-cannabis-corporation-recaps-2018-and-gives-a-glimpse-into-2019/?fbclid=IwAR3RPRQsyYIk4d4LG5mj1iYYMxQPIjfe6gpsqLPSKkOfeqv6wMPxEyblkaY

[JohnCM]

Liberty Health Sciences Opens Dispensary in Heart of Miami on Bird Road

Dec 11, 2018

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com, a provider of high quality cannabis, announced that the Company has opened its first south Florida dispensary today in the heart of Miami. The new dispensary provides customers in Miami-Dade County, the most populous county in Florida, access to premium quality medical marijuana products and educational services.

Located at 6827 Bird Road, Miami, FL., the state-of-the art dispensary is open Monday through Friday, 10 a.m. to 7p.m., Saturday, 10 a.m. to 5 p.m., and Sunday 12 p.m. to 5 p.m. Bird Road is one of the oldest and busiest state roads in Miami, with traffic exceeding 70,000 vehicles per day. It is a primary artery that feeds the main suburbs in Miami such as Coral Gables, West Miami, South Miami, Westchester, and Kendall. In addition to the Miami location, Liberty plans to open 3 more dispensaries this month with more to come in 2019, all subject to the receipt of Florida Department of Health approvals.

"Liberty remains committed to ensuring that its premium quality medical marijuana products and educational services are accessible to the more than 2.7 million people who call South Florida home," said George Scorsis, CEO of Liberty Health Sciences. "When people come to our dispensaries, they know they will find the highest quality medicinal cannabis. They also trust that they are going to have access to the best brands in any category, including PAX and Mary's Medicinals products.

"No other company has a brand-house and selection like ours. This demonstrates that not only do our partner brands trust and believe in us to deliver against their goals and objectives, but that consumers also have a diverse selection of the best products available," said George Scorsis, CEO of Liberty Health Sciences.

In order to keep up with the growing footprint of dispensaries and patient demand, Liberty is expanding the Company's production capacity of the Liberty 360 facility in Gainesville, Florida, expected to be completed in stages in 2019. The Liberty 360 operation currently has 20,000 square feet of cultivation space on-line at the facility and the next phase of 80,000 square feet is expected to be completed by February 2019. The Company has also greatly expanded its R&D capabilities at the Liberty 360 facility in terms of delivery systems and continues to develop different formats of cannabis.

About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty's measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.

SOURCE Liberty Health Sciences Inc.

View original content: www.newswire.ca/en/releases/archive/December2018/11/c7788.html

[JohnCM]

Authorized Shares
75,000,000
12/01/2018

Outstanding Shares
54,577,854
12/01/2018

[jedijazz]

$IDVV’s goal of entering the CBD market is to diversify the Company and position themselves in the CBD Space. https://finance.yahoo.com/news/idvv-enter-growing-cbd-market-135000834.html?soc_src=hl-viewer&soc_trk=tw

[JohnCM]

After Sharp Share Price Decline, Curaleaf to Repurchase up to $50 Million of Subordinated Voting Shares

December 5, 2018 at 9:46 am
Published by NCV Newswire

Curaleaf Announces Launch of Share Buyback Program

VANCOUVER, British Columbia, Dec. 5, 2018 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCBB: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the United States, announced today its intention to commence a normal course issuer bid (“NCIB” or the “Bid”) to expend up to an aggregate of USD $50 million on the purchase of subordinated voting shares (the “Subordinated Voting Shares”). The actual number of Subordinated Voting Shares that may be purchased under the Bid and the exact timing of any such purchases will be determined by the Company.

The Company is commencing the Bid because it believes that, from time to time, the market price of its Subordinated Voting Shares does not reflect the underlying value of the Company’s business and future prospects. The Company believes that, at such times, the repurchase of its Subordinated Voting Shares for cancellation would be in the best interests of its shareholders.

Pursuant to the NCIB, the Company may, if considered advisable, purchase the Subordinated Voting Shares through the facilities of the Canadian Securities Exchange (“CSE”) and/or alternative trading systems, from time to time over the next 12 months, and shall not, in any event, exceed 5% of the issued and outstanding Subordinated Voting Shares. The Company has appointed GMP Securities L.P. to coordinate and facilitate its NCIB purchases. Purchases may commence through the CSE and/or alternative trading systems on December 12, 2018 and will conclude on the earlier of the date on which purchases under the bid have been completed or December 12, 2019. All Subordinated Voting Shares purchased by the Company will be cancelled.

About Curaleaf Holdings, Inc.

The Company is the parent of Curaleaf, Inc., a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf has a presence in 12 states.

Curaleaf operates 34 dispensaries, 12 cultivation sites and 10 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Curaleaf leverages its extensive research and development capabilities to distribute premium cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. Curaleaf is committed to being the industry’s leading resource in education and advancement through research and advocacy.

[JohnCM]

????????????????????????????? what do you make of this?



The DOW absolutely had to take a breather. Is the froth off the top?

[JohnCM]

What will decide the direction of MJ stocks this week?

#1. ETF ( funds ) are trading at their lows. = headed higher.
#2. Aphria has recovered somewhat. = headed higher.
#3. Another BIG investment ( Cronos ). = headed higher.
#4. Direction of the DOW and NASDAQ ????????????????????????????????



Green Market Report's Marijuana Money December 7, 2018

Marijuana Money

Big Tobacco Spends C$2.4 Billion To Invest In Cannabis

Acreage Holdings Invests $160 Million In Multi-State Distributor Form Factory

The Daily Hit: December 6, 2018

The trading week was shortened as markets were closed on Wednesday to honor the funeral of the 41st president George HW Bush. Probably best since stocks took a beating on Tuesday.

On Monday, Cresco Labs became the latest multi-state operator to begin publicly trading on the Canadian Securities Exchange. Using the ticker CL, the stock opened at $8.50 and was lately trading at $C6.57.

Cronos Group stock skyrocketed after the company confirmed that it was speaking with tobacco giant Altria. While there is no additional news of a deal, it is anticipated to be a big one. Tobacco companies have shied away from cannabis until now presumably waiting until it was federally legal. It seems these companies have decided that to snooze is to lose.

Conversely, Aphria, which had been rumored in October to be speaking with Altria came under short seller attack. The stock plunged after Gabriel Grego called the company worthless. Eight Capital also cut its price target from C$22 to C$7 and the securities lawyers are lining up for business.

TILT Holdings began trading this week on the CSE using the symbol TILT. It also acquired cannabis distributor Blackbird for $50 million. Blackbird works with 250 wholesale and retail cannabis companies in Nevada and California. The company plans to expand into Massachusetts and Arizona and further in California.

High Times came to an agreement with THC Holdings to convert $28.6 million worth of debt to Class A common stock. The debt has been hanging over High Times and this removes the pressure of making those payments.

Origin House acquired craft cannabis company Cub CityCity for roughly $7 million.

Money continues to flow into the sector.

Ascend Wellness raised $40 million and believes this is one of the largest raises in Massachusetts. The company will use the money for expansion into other states.

OG DNA genetics raised $35 million.

[budfoxfun]

$TXHD Key technology advancements were announced including the Company’s architecture of its Artificial Intelligence (AI) layer for the Smart Automated Messaging (SAM) platform. This process is expected to be complete in Q1 of 2019. In addition to AI, the Company announced it is integrating Rich Communication Services, or RCS, into the SAM platform creating a trifecta of technology – SMS, RCS and AI in one platform. The RCS integration is also expected to be completed in Q1 of 2019.

Textmunication Provides 2018 Year-End Corporate Update https://finance.yahoo.com/news/textmunication-provides-2018-end-corporate-140000262.html

[JohnCM]

Liberty Health was mentioned in Alphria article and I bought on weakness $0.93

[greenwillow]

Exciting.

We've been talking about for over a year.

[JohnCM]

Arbitrage play ...

Just a matter of time ...

BIG

tobacco
pharma
beverage
alcohol

Altria Reportedly In Talks To Buy Cronos Group

Benzinga 3-Dec 12:39 PM

[PotterBanker]

https://www.financialnewsmedia.com/change-in-attorney-general-could-mean-a-cannabis-revolution-in-the-us/

[jedijazz]

$IDVV #Green CBD-derived products are projected by some to rapidly expand up to $22 Billion by 2022, IDVV has been working with a firm to effectively enter into the CBD market in 2019, as well as develop a plan for significant distribution including an affiliate program and identifying influencers. The CBD marketplace consists of dozens of product lines and is surpassing the THC market in terms of margins, without the regulations and the barrier to the market. We look forward to announcing our complete plan shortly." https://finance.yahoo.com/news/idvv-enter-growing-cbd-market-135000834.html